Biapenem for injection
Function and Efficacy
Biapenem is a carbapenem antibiotic that exerts its antibacterial effect by inhibiting the synthesis of bacterial cell walls. It has broad-spectrum antibacterial activity against gram-positive and gram-negative aerobic and anaerobic bacteria. Biapenem is stable to human renal dehydropeptidase-I (DHP-I) and can be administered alone without the need for combination with DHP-I inhibitors.
Ingredients
The main ingredient of this product is biapenem, without excipients. Chemical name: (-)6-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt. Molecular formula: C15H18N4O4S Molecular weight: 350.40
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| BiapenemIngredients |
Biapenem is a carbapenem antibiotic that exerts its antibacterial effect by inhibiting the synthesis of bacterial cell walls. It has broad-spectrum antibacterial activity against gram-positive and gram-negative aerobic and anaerobic bacteria. Biapenem is stable to human renal dehydropeptidase-I (DHP-I) and can be administered alone without the need for combination with DHP-I inhibitors. More |
120410-24-4 | 8 |
Indication
1. Strains sensitive to this product include: Staphylococcus, Streptococcus, Pneumococcus, Enterococcus (except Enterococcus faecium), Moraxella, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Haemophilus influenzae, Pseudomonas aeruginosa, Actinomyces, Peptostreptococcus, Bacteroides, Prevotella, Fusobacterium, etc. 2. This product is suitable for the treatment of sepsis, pneumonia, lung abscess, secondary infection caused by chronic respiratory diseases, refractory cystitis, pyelonephritis, peritonitis, gynecological adnexitis, etc. caused by sensitive bacteria.
Usage and Dosage
Dissolve 0.3g of biapenem in 100ml of normal saline or glucose injection and drip intravenously. Adults take 0.6g per day, drip twice, 30-60 minutes each time. The dosage can be appropriately increased or decreased according to the patient's age and symptoms. However, the maximum daily dosage should not exceed 1.2g.
Adverse Reactions
According to foreign literature reports, the most common adverse reactions are rash/skin itching, nausea, vomiting and diarrhea. Among 2348 cases, 64 cases (2.7%) had adverse reactions, mainly manifested as rash (1.0%), diarrhea (0.7%), etc. Among 2287 cases, 304 cases (13.3%) had 522 abnormal clinical test indicators, mainly manifested as increased ALT (GPT) (144 cases, 6.3%), increased AST (GOT) (93 cases, 4.1%), eosinophilia (77 cases, 3.4%), etc. Serious adverse reactions of this product include: 1. Shock (pneumonia (0.1-5%), PIE syndrome; 3. Severe enteritis such as pseudomembranous colitis; 4. Muscle spasms, impaired consciousness;
Precautions
(1) Patients who are allergic to this product are contraindicated. (2) Patients who are taking sodium valproate are contraindicated.
Drug Interactions
When this product is used in combination with valproic acid, it may lead to a decrease in the blood concentration of valproic acid, which may cause recurrence of epilepsy. Therefore, this product should not be used in combination with valproic acid preparations.
Storage
Keep in a light-proof and airtight container.
Packaging Specification
0.3g
Validity Period
12 months
Manufacturer
CSPC OUYI Pharmaceutical Co., Ltd.
-
Founded in:
2001-03-29 -
Address:
No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone -
Tax NO.:
91130100601289268L -
Registered Funds:
298 million yuan -
Website:
-
Email: